
The deal adds five US sites and about 1,100 employees, more than doubling Lonza’s US network and filling a gap in US bioconjugation capacity the company flagged weeks earlier.
Franz B. Humer, chairman of the board of directors of the Roche Group, will not stand for re-election to the Board in 2014.






